Reakcja polekowa na lamotryginę – opis przypadku
Słowa kluczowe:
lamotrygina, zapalenie gardła, reakcja polekowaAbstrakt
Aim. The objective is to analyze the lamotrigine-induced drug reaction, which, according to the Regi-SCAR-Group Diagnosis Score for DRESS can be classified as possible DRESS syndrome (drug hypersensitivity syndrome consisting of drug rash, eosinophilia and systemic symptoms), complicated by rarely described in literature severe pharyngitis.
Method. The analysis of the clinical case and medical documentation.
Results. Patient aged 52, diagnosed with type I bipolar disorder, has been treated with valproic acid and/or lithium for 4 years. Three weeks after the beginning of lamotrigine therapy, he developed an erythematous maculopapular rash with fever, hypereosinophilia, leucopenia, lymphopenia with atypical lymphocytes, stomatitis and pharyngitis.
Conclusions. Severe stomatitis and pharyngitis are rarely reported symptoms of the lamotrigine-induced drug reaction.
No predictive factors for serious adverse drug reactions have yet been identified. Therefore, an individual risk-benefit assessment should be performed carefully before introducing the new medication into the patient’s therapy.
Bibliografia
1. Lamotriginum. Charakterystyka produktu leczniczego. Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Pro-duktów Biobójczych. http://www.urpl.gov.pl/drugs
2. Faught E., Morris G., Jacobson M., French J. i in. Adding lamotrigine to valproate: incidence of rash and other adverse ef-fects. Postmarketing Antiepileptic Drug Survey (PADS) Group. Epilepsia, 1999; 40(8): 1135-40.
3. Hirsch L.J., Weintraub D.B., Buchsbaum R., Spencer H.T. i in. Predictors of Lamotrigine-associated rash. Epilepsia, 2006; 47(2): 318-22.
4. Adler C.M., Fleck D.E., Brecher M., Strakowski S.M. Safety and tolerability of quetiapine in the treatment of acute mania in bipo-lar disorder. J Affect Disord, 2007; 100 Suppl 1: S15–22.
5. Vieta E., Suppes T., Eggens .I, Persson I. i in. Efficiency and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord, 2008; 109(3): 251-63.
6. Chang L.R., Chang H.C., Lin Y.H. Quetiapine- and valproate-associated neutropenia and thrombocytopenia after lamotrigine-induced Ste-ven-Johnson syndrome. J Clin Psychopharmacol, 2012;32(1):133-4.
7. Pereira de Silva N., Piquioni P., Kochen S., Saidon P. Risk factors associated with DRESS syndrome produced by aro-matic and non-aromatic antipiletic drugs. Eur J Clin Pharmacol, 2011;67(5):463-70.
8. Saczonek A., Zdrodowska-Stefanow B. Drug hypersensitivity syndrome – odczyn polekowy z objawami układowymi. Wiad Lek, 2005; 58(5-6): 324-30.
9. Amante M.F., Filippini A.V., Cejas N., Lendoire J., Imventarza O., Parisi C. Dress syndrome and fulminant hepatic failure induced by lamotrigine. Ann Hepatol, 2009; 8(1): 75-7.
10. Roujeau J.C., Allanore L., Liss Y. Severe Cutaneous Adverse Reac-tions to drugs (SCAR): Definition, Diagnostic Criteria, Genetic Predisposition. Dermatol Sinica, 2009; 27: 203-209.
11. Taillia H., Alla P., Fournier B., Bounolleau P. i in. Anticonvulsant hypersensitivity syndrome and lamotrigine-associated anticon-vulsant hypersensitivity syndrome. Rev Neurol (Paris), 2009; 165(10): 821–857.
12. Kardaun S.H., Sidoroff A., Valeyrie-Allanore L. i in. Variability in the clinical pattern of cutaneous side-effects of drugs with sys-temic symptoms: does a DRESS syndrome really exists? Br J Dermatol, 2007; 156: 609-11.
13. Shiohara T., Inaoka M., Kano Y. Drug-induced hypersensitivity syndrome (DIHS): A reaction induced by a complex interplay among herpesviruses and antiviral and anti drug immune re-sponses. Allergol Int, 2006; 55: 1-8.
14. Kito Y., Ito T., Hashizume H, Tokura Y. High-dose intravenous immunoglobulin monotherapy for drug-induced hypersensitivity syndrome. Acta Derm Venereol, 2012; 92(1): 100-101.
15. Gomułka K., Kuliczkowska D., Cisło M., Woźniak Z., Panaszek B. Zespół nadwrażliwości indukowanej lekami - przegląd pi-śmiennictwa i opis przypadku. Pneumonol Alergol Pol, 2011; 79 (1): 52-56.
16. Renke J., Sobkowiak M., Wołowska E. Przypadki poważnych działań niepożądanych po zastosowaniu farmakoterapii i za-burzeń zachowania i snu u dzieci. Forum Med. Rodz, 2011; 5 (5): 424-428.
17. Setkowicz M., Dziunikowska A., Woroń J., Wojas-Pelc A. Lamotry-gina – lek przeciwdrgawkowy nowej generacji prawdopodobną przyczyną ostrej dermatozy polekowej – opis przypadku. Post Dermatol Alergol, 2009; XXVI, 6: 555-560.
18. McCormack M., Urban T.J., Shianna K.V., Walley N. i in. Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. Phar-macogenomics, 2012; 13(4):399-405.
19. Cheung Y.K., Cheng S.H., Chan E.J., Lo S.V. i in. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia, 2013; 54(7):1307-14.
